Chen Wen-Jie, Tang Rui-Xue, He Rong-Quan, Li Dong-Yao, Liang Liang, Zeng Jiang-Hui, Hu Xiao-Hua, Ma Jie, Li Shi-Kang, Chen Gang
Department of Thoracic and Cardiovascular Diseases, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China.
Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China.
Oncotarget. 2017 May 22;8(37):61282-61304. doi: 10.18632/oncotarget.18058. eCollection 2017 Sep 22.
Lung squamous cell carcinoma (LUSC) accounts for a significant proportion of lung cancer and there have been few therapeutic alternatives for recurrent LUSC due to the lack of specific driver molecules. To investigate the prospective role of lncRNAs in the tumorigenesis and progression of LUSC, the aberrantly expressed lncRNAs were calculated based on The Cancer Genome Atlas RNA-seq data. Of 7589 lncRNAs with 504 LUSC cases, 884 lncRNAs were identified as being aberrantly expressed (|log2 fold change| >2 and adjusted P<0.05) by DESeq R. The top 10 lncRNAs with the highest diagnostic value were ,, , ,, , ,, , and . In addition to the significant roles in the carcinogenesis of LUSC, several lncRNAs also played vital parts in the survival and progression of LUSC. , , and were closely related to the survival time of LUSC. Furthermore, and could distinguish the LUSC at early stage from that at advanced stage. The prospective molecular assessment of key lncRNAs showed that a certain series of genes could be involved in the regulation network. Furthermore, the OncoPrint from cBioPortal indicated that 14% (69/501) LUSC cases with genetic alterations could be obtained, including amplification, deep deletion and mRNA upregulation. More interestingly, the cases with genetic alterations had a poorer survival as compared to those without alterations. Overall, the study propounds a potentiality for interpreting the pathogenesis and development of LUSC with lncRNAs, and provides a novel platform for searching for more capable diagnostic biomarkers for LUSC.
肺鳞状细胞癌(LUSC)在肺癌中占相当大的比例,由于缺乏特异性驱动分子,复发性LUSC的治疗选择很少。为了研究lncRNAs在LUSC肿瘤发生和进展中的潜在作用,基于癌症基因组图谱RNA测序数据计算异常表达的lncRNAs。在7589个lncRNAs和504例LUSC病例中,通过DESeq R鉴定出884个lncRNAs异常表达(|log2倍数变化|>2且校正P<0.05)。诊断价值最高的前10个lncRNAs分别是 、 、 、 、 、 、 、 和 。除了在LUSC致癌过程中发挥重要作用外,一些lncRNAs在LUSC的生存和进展中也起着至关重要的作用。 、 、 和 与LUSC的生存时间密切相关。此外, 和 可以区分早期LUSC和晚期LUSC。关键lncRNAs的前瞻性分子评估表明,一系列特定基因可能参与调控网络。此外,cBioPortal的OncoPrint显示,可以获得14%(69/501)有基因改变的LUSC病例,包括扩增、深度缺失和mRNA上调。更有趣的是,与没有基因改变的病例相比,有基因改变的病例生存情况更差。总体而言,该研究提出了用lncRNAs解释LUSC发病机制和发展的可能性,并为寻找更有效的LUSC诊断生物标志物提供了一个新平台。